Duloxetine associated with smoking cessation [3]

Annals of Pharmacotherapy

Volumn 39, Issue 9, 2005, Pages 1578-1579

  Marcil, William A ^a   Petty, Frederick ^a,b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DULOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; CASE REPORT; CIGARETTE SMOKING; DEPRESSION; DRUG EFFECT; HUMAN; LETTER; MALE; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; SMOKING CESSATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; DEPRESSION; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS; SMOKING CESSATION; THIOPHENES;

EID: 23944474054     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G101     Document Type: Letter

References (4)

1. Hughes J, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004;4:1-55.
2. Stahl S. Neurotransmission of cognition. Part 1, dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry 2003;64:4-5.
3. Bymaster F, Dreshfield-Ahmad MS, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, et al. Comparitive affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptors subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-80.
4. Preskorn S. Duloxetine. J Psychiatr Pract 2004;10:375-85.